Show simple item record

dc.contributor.authorChrisanthar, Ranjaneng
dc.contributor.authorKnappskog, Stianeng
dc.contributor.authorLøkkevik, Erikeng
dc.contributor.authorAnker, Gun Birgittaeng
dc.contributor.authorØstenstad, Bjørneng
dc.contributor.authorLundgren, Steinareng
dc.contributor.authorRisberg, Terjeeng
dc.contributor.authorMjaaland, Ingvileng
dc.contributor.authorSkjønsberg, Gudbrandeng
dc.contributor.authorAas, Turideng
dc.contributor.authorSchlichting, Elleneng
dc.contributor.authorFjösne, Hans E.eng
dc.contributor.authorNysted, Arneeng
dc.contributor.authorLillehaug, Johaneng
dc.contributor.authorLønning, Per Eysteineng
dc.date.accessioned2012-02-27T13:43:28Z
dc.date.available2012-02-27T13:43:28Z
dc.date.issued2011-04-27eng
dc.identifier.citationPLoS ONE 6(4): e19249en
dc.identifier.issn1932-6203eng
dc.identifier.urihttp://hdl.handle.net/1956/5648
dc.description.abstractBackground: TP53 mutations have been associated with resistance to anthracyclines but not to taxanes in breast cancer patients. The MDM2 promoter single nucleotide polymorphism (SNP) T309G increases MDM2 activity and may reduce wildtype p53 protein activity. Here, we explored the predictive and prognostic value of TP53 and CHEK2 mutation status together with MDM2 SNP309 genotype in stage III breast cancer patients receiving paclitaxel or epirubicin monotherapy. Experimental Design: Each patient was randomly assigned to treatment with epirubicin 90 mg/m2 (n= 109) or paclitaxel 200 mg/m2 (n = 114) every 3rd week as monotherapy for 4–6 cycles. Patients obtaining a suboptimal response on first-line treatment requiring further chemotherapy received the opposite regimen. Time from last patient inclusion to follow-up censoring was 69 months. Each patient had snap-frozen tumor tissue specimens collected prior to commencing chemotherapy. Principal Findings: While TP53 and CHEK2 mutations predicted resistance to epirubicin, MDM2 status did not. Neither TP53/ CHEK2 mutations nor MDM2 status was associated with paclitaxel response. Remarkably, TP53 mutations (p = 0.007) but also MDM2 309TG/GG genotype status (p = 0.012) were associated with a poor disease-specific survival among patients having paclitaxel but not patients having epirubicin first-line. The effect of MDM2 status was observed among individuals harbouring wild-type TP53 (p = 0.039) but not among individuals with TP53 mutated tumors (p.0.5). Conclusion: TP53 and CHEK2 mutations were associated with lack of response to epirubicin monotherapy. In contrast, TP53 mutations and MDM2 309G allele status conferred poor disease-specific survival among patients treated with primary paclitaxel but not epirubicin monotherapy.en
dc.language.isoengeng
dc.publisherPublic Library of Scienceeng
dc.rightsAttribution CC BYeng
dc.rights.urihttp://creativecommons.org/licenses/by/2.5/eng
dc.titlePredictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxeleng
dc.typePeer reviewedeng
dc.typeJournal articleeng
dc.subject.nsiVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762eng
dc.rights.holderCopyright 2011 Chrisanthar et al.
dc.type.versionpublishedVersioneng
bora.peerreviewedPeer reviewedeng
bora.cristinID839750eng
bibo.doihttp://dx.doi.org/10.1371/journal.pone.0019249eng
dc.identifier.cristinID839750eng
dc.identifier.doihttp://dx.doi.org/10.1371/journal.pone.0019249


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution CC BY
Except where otherwise noted, this item's license is described as Attribution CC BY